What Are Growth Hormone Peptides?
Growth hormone peptides are a class of synthetic research compounds designed to stimulate the pituitary gland's release of endogenous growth hormone (GH). They do this through two distinct receptor pathways — the growth hormone-releasing hormone receptor (GHRHR) and the growth hormone secretagogue receptor (GHSR, also called the ghrelin receptor) — and researchers frequently study them in combination to engage both axes simultaneously.
By: Palmetto Peptides Research Team | Date: March 11, 2026
For research purposes only. Not intended for human or veterinary use. Not for human consumption.
What Two Pathways Do Growth Hormone Peptides Use?
Growth hormone peptide research splits cleanly into two mechanistic families: GHRH analogs, which mimic the body's own growth hormone-releasing hormone and bind the GHRHR on pituitary somatotrophs, and GHRPs (growth hormone-releasing peptides), which instead bind the ghrelin receptor (GHSR-1a) to trigger GH secretion through a separate intracellular cascade.
GHRH Receptor Pathway (GHRHR agonists)
- Sermorelin — a 29-amino acid analog of native GHRH(1-44), binding GHRHR and stimulating pulsatile GH release. Shorter active window makes it useful for studying physiological GH pulse dynamics.
- CJC-1295 (No DAC) — a modified GHRH analog with four amino acid substitutions improving stability. Produces pulsatile GH release with a half-life in the range of 30 minutes, preserving physiological pulse patterns in study models.
- CJC-1295 with DAC — the same peptide backbone, but conjugated with a Drug Affinity Complex (DAC) via a lysine residue at position 30. The DAC component binds covalently to serum albumin, extending the half-life to approximately 6–8 days. This shifts the GH release profile from pulsatile to sustained — a distinct experimental variable.
Ghrelin Receptor Pathway (GHSR agonists)
- Ipamorelin — a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and one of the most selective GHRPs studied to date. In preclinical models, Ipamorelin demonstrates minimal co-stimulation of cortisol or prolactin compared to earlier GHRPs, making it a cleaner research tool for isolating GH-specific signaling.
- Hexarelin — a six-amino acid GHRP (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) with strong GHSR binding affinity. Beyond GH secretion, Hexarelin has attracted research interest for its interactions with the CD36 receptor and scavenger receptor class B, where studies in rodent models have examined cardioprotective signaling independent of its GH-releasing activity.
How Does CJC-1295 with DAC Differ from CJC-1295 No DAC?
The DAC modification fundamentally changes the pharmacokinetic profile: CJC-1295 No DAC produces short, pulsatile GH bursts that approximate natural release patterns, while CJC-1295 with DAC maintains elevated GH stimulation continuously over days due to albumin binding.
The Drug Affinity Complex technology works via a succinimidyl carbonate group on the DAC linker that forms a stable amide bond with serum albumin's lysine-525 residue, essentially using the body's most abundant serum protein as a long-lived carrier. For researchers studying chronic vs. acute GH secretagogue effects, this pharmacokinetic distinction is the primary experimental variable between the two compounds.
Why Do Researchers Combine a GHRH Analog with a GHRP?
The two pathways are mechanistically complementary — GHRHR activation increases cAMP and PKA signaling in somatotrophs, while GHSR activation engages Gq/11-coupled PLC-IP₃ pathways and also suppresses somatostatin release. In rodent studies, combining a GHRH analog with a GHRP produces synergistic GH release significantly greater than either compound alone.
This synergy is one of the most replicated findings in GH secretagogue research. The dual-pathway approach allows investigators to study additive or synergistic GH signaling while independently manipulating each pathway's contribution.
What Makes Ipamorelin Distinct Among GHRPs?
Ipamorelin is the most receptor-selective GHRP studied in preclinical models — it produces robust GH release with minimal stimulation of ACTH, cortisol, or prolactin at research-relevant concentrations, unlike earlier GHRPs such as GHRP-2 and GHRP-6, which show broader secretagogue activity.
This selectivity profile is documented in peer-reviewed research (Raun et al., European Journal of Endocrinology, 1998) and makes Ipamorelin a preferred tool when researchers need to isolate GH axis effects without confounding activation of the HPA axis.
Comparison: Growth Hormone Peptides at a Glance
| Compound | Receptor Target | Half-Life | GH Release Pattern | Notable Research Signal |
|---|---|---|---|---|
| Sermorelin | GHRHR | ~10–20 min | Pulsatile | Physiological GH pulse modeling |
| CJC-1295 No DAC | GHRHR | ~30 min | Pulsatile | Stable GHRH analog for acute studies |
| CJC-1295 + DAC | GHRHR (albumin-bound) | ~6–8 days | Sustained | Chronic GH stimulation models |
| Ipamorelin | GHSR-1a | ~2 hours | Pulsatile | High GH selectivity, minimal cortisol/prolactin |
| Hexarelin | GHSR-1a / CD36 | ~1–2 hours | Pulsatile | Cardioprotective research signal |
Frequently Asked Questions
Q: Are growth hormone peptides the same as synthetic growth hormone (HGH)?
A: No. Growth hormone peptides stimulate the pituitary to release the body's own GH; they do not supply exogenous GH directly. Synthetic HGH (recombinant somatropin) replaces GH directly and bypasses the pituitary axis entirely.
Q: What is the ghrelin receptor (GHSR-1a)?
A: The growth hormone secretagogue receptor type 1a is a G protein-coupled receptor expressed primarily in the pituitary and hypothalamus. It is the endogenous receptor for ghrelin, a 28-amino acid peptide produced mainly in the stomach. GHRPs like Ipamorelin and Hexarelin bind GHSR-1a to stimulate GH release through a pathway distinct from GHRHR.
Q: Why does CJC-1295 + DAC have such a long half-life?
A: The Drug Affinity Complex creates a covalent bond between the peptide and serum albumin (MW ~67 kDa), which has a natural half-life of approximately 19 days. By associating with albumin, the peptide is protected from proteolytic degradation and renal clearance.
Q: What does Hexarelin's CD36 activity mean for research?
A: Hexarelin has been shown in animal models to bind CD36 (a scavenger receptor on cardiomyocytes and macrophages) and exhibit cardioprotective effects that appear independent of GH secretion, making it of interest for cardiac biology research.
Q: Can GHRH analogs and GHRPs be studied together?
A: Yes — in preclinical models, combination protocols are well-documented and produce synergistic GH release. The two pathways engage different intracellular cascades and their co-activation has additive to synergistic effects on pituitary GH output.
Explore Palmetto Peptides Growth Hormone Research Compounds
- Ipamorelin Research Peptide
- CJC-1295 + DAC Research Peptide
- CJC-1295 No DAC Research Peptide
- Sermorelin Research Peptide
- Hexarelin Research Peptide
All products are research-grade, COA verified, and intended for laboratory research use only.